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Abstract
Burning mouth syndrome (BMS) is a relatively common chronic disease of unclear etiopathogenesis. It is defined as a 
distinctive nosological entity that includes all forms of burning sensation in the mouth, including stinging sensation or 
pain, in association with an oral mucosa that appears clinically normal, in the absence of local or systemic diseases.
It was hypothesized that psychological factors could influence its appearance, but also physiological factors, with some 
authors suggesting a neuropathic etiology.
Regarding the treatment of BMS, benefits were found in individual or group psychotherapy, as well as in 
psychopharmacological interventions, however its current therapeutic approach is not completely satisfactory.
In this paper we describe two cases of BMS and discuss the possible etiopathogenesis and current therapeutic 
approaches.
Resumo
A síndrome da boca ardente (SBA) é uma doença crónica relativamente comum de etiopatogenia desconhecida. É 
definida como uma entidade nosológica distinta que inclui todas as formas de sensação de ardência bucal, incluindo 
sensação de picada ou dor, em associação com uma mucosa oral que aparenta ser clinicamente normal, na ausência de 
doenças locais ou sistémicas.
Foi colocada a hipótese de que fatores psicológicos pudessem influenciar o seu aparecimento, assim como fatores 
fisiológicos, com alguns autores a sugerir uma etiologia neuropática.
No que diz respeito ao tratamento da SBA foram encontrados benefícios em psicoterapia individual ou de grupo, assim 
como em intervenções psicofarmacológicas, no entanto a sua abordagem terapêutica atual não é totalmente satisfatória.
Neste artigo descrevemos dois casos de SBA e discutimos a sua possível etiopatogenia e abordagens terapêuticas 
vigentes.
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Burning mouth syndrome (BMS) is a chronic disease of un-
clear etiopathogenesis,1 also known as stomatodynia, oral 
dysaesthesia, glossodynia, glossopyrosis, and stomatopy-
rosis.2 The International Association for the Study of Pain 
and International Headache Society defines it as a distinc-
tive nosological entity that comprises all forms of burning 
sensation in the mouth, includingcomplaints described as 
stinging sensation or pain, in association with a normal oral 
mucosa, without the presence of local or systemic diseases.2
It is a relatively common disease, especially amongst post-
menopausal women, estimated to affect from 0.7% to 4.6% 
of the general population.1
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The main complaint in BMS patients is the presence of an 
oral burning sensation, which may affect multiple sites of 
the oral cavity, with the tongue being the most frequently 
affected site,1 especially the anterior 2/3 and the extremity, 
as well as the dorsum and the anterolateral margins. Often 
the anterior hard palate, the lip mucosa and the mandibular 
alveolar regions are also affected.3
The burning sensation is often bilateral and symmetrical 
and does not respect the anatomical distribution of a pe-
ripheral sensory nerve.3 It can be present during almost all 
day and often persists for many years.4 The pain may vary 
in its intensity and can improve with food intake.5 Xeros-
tomia and dysgeusia are also frequent, and can constitute 
a diagnostic triad, although most cases present oligo or 
monosymptomatic.5
Although not consensual, it has been hypothesized that 
psychological factors could explain the origin of the 
symptoms in this syndrome, with several studies demon-
strating a high frequency of comorbidity with psychiatric 
disorders. Depression appears to be the most prevalent 
psychiatric disease among patients with BMS, but anxious 
disorders, “cancerophobia” and hypochondriasis are also 
very common,1 as well as personality disorders,3 which 
suggests that BMS may constitute a functional pain syn-
drome. A large percentage of these patients have a history 
of psychiatric hospitalization and are more likely to be un-
der psychiatric treatment, often initiated before the onset 
of BMS symptoms.3 Increasing evidence also suggests that 
pain in idiopathic BMS may have a neuropathic etiology.3,6
It is important to emphasize that BMS is an exclusion diag-
nosis requiring the evaluation of other potential causes for 
the symptoms, such as salivary glands, endocrine and con-
nective tissue diseases, gastroesophageal acid reflux, drug 
side effects (e.g. angiotensin ‑converting enzyme inhibitors, 
antibiotics, antiretrovirals), neurological changes, nutrition-
al deficiencies, allergies, infections, climacteric, chemo-
therapy and radiotherapy, and mechanical factors (tongue 
trauma – poorly fitting dental prosthetics, piercings).4,7
Regarding the treatment of BMS, although it is not com-
pletely satisfactory and total remission is unusual, benefits 
were found with both individual and group psychotherapy, 
as well as with psychopharmacological interventions,1 
including antidepressants (tricyclic, selective serotonin re-
uptake inhibitors  ‑ SSRI, serotonin noradrenaline reuptake 
inhibitors – SNRI); benzodiazepines (systemic use or local 
application of clonazepam); anticonvulsants; local capsai-
cin and alpha lipoic acid.6
In this paper we describe two cases of BMS occurring in 
patients with long history of depression, who received 
treatment for this disorder, but only improved their BMS 
symptoms after an approach that did not include antide-
pressants. This suggests that BMS may not be a mere so-
matic manifestation of depression or anxiety, although the 
comorbidity is frequent.
Case Reports
Case 1: 70 ‑year ‑old female patient with 11 ‑year psychiatric 
history of recurrent major depression, of mild to moderate 
severity, without psychotic features and in full remission, 
and generalized anxiety disorder. She also underwent total 
thyroidectomy due to thyroid follicular carcinoma five years 
before, had a history of hypertension and dyslipidemia, 
and was medicated with levothyroxine, lisinopril + hydro-
chlorothiazide and simvastatin. She suddenly developed 
complaints of burning and pain sensations in the tongue´s 
dorsum that were persistent during the day but attenuated at 
mealtime. The onset of pain was temporally not compatible 
with medication changes. Because of these symptoms she 
appealed to several physicians of various specialties includ-
ing gastroenterology, stomatology, endocrinology and neu-
rology, who ruled out gastroesophageal acid reflux, salivary 
glands alterations, endocrine and connective tissue diseases, 
nutritional deficiencies, neurological changes, allergies and 
infectious causes. Initially, as doctors did not know what 
was causing the pain and suspected of pyrosis or tongue 
infection, multiple types of drugs were prescribed including 
proton pump inhibitor, sucralfate, antifungal and antiviral, 
but they were completely unsuccessful. She was finally re-
ferred to a psychiatry specialist and became apparent that 
the burning sensation seemed to be related with anxiety ag-
gravation in the context of adverse life events. For the pain 
and anxious symptoms she was medicated with pregabalin, 
benzodiazepines and SSRI without total symptom relief. 
She began to reveal more significant improvements in BMS 
symptoms after introduction of carbamazepine 200 mg/day, 
chosen for being a recommended therapy for neuropathic 
pain.
Case 2: 58 ‑year ‑old female patient who was being fol-
lowed for two years in psychiatry and psychology con-
sultations for recurrent major depressive disorder of mild 
to moderate severity, without psychotic features and with 
anxious distress, that had started 11 years before. She be-
gan to develop xerostomia and lingual burning complaints 
in a time of worsening depressed mood and increasing 
levels of anxiety in the context of general health concerns, 
having been diagnosed with adjustment disorder with 
mixed anxiety and depressed mood. She had a history of 
dyslipidemia and gastroesophageal reflux, for which she 
was successfully medicated for several years with simvas-
tatin, proton pump inhibitor and sucralfate. The onset of 
the pain was not temporally compatible with medication 
changes. She was observed by various specialties includ-
ing stomatology, endocrinology and gastroenterology, 
and salivary glands alterations, endocrine and connec-
tive tissue diseases, nutritional deficiencies, neurological 
changes, allergies and infectious causes were excluded, 
without indication for further investigation. After multiple 
therapeutic adjustments with SSRI and benzodiazepines, 
the pain complaints improved after introduction of topical 
application of 2 mg of clonazepam in the mouth, a recom-
mended therapy for BMS.
Discussion
Both patients presented had clinical characteristics sugges-
tive of BMS. They had a significant history of depressive 
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and anxious symptoms and reported worsening of pain 
complaints coincident with worsening mood, which sug-
gests that BMS can have a psychogenic origin. However, 
on the other hand, given the favorable response to drugs 
indicated for the treatment of neuropathic pain (the first 
patient only experienced pain relief with carbamazepine, 
after unsuccessful antidepressant and anxiolytic prescrip-
tions), this may indicate that BMS may not merely be a 
somatic manifestation of depression or anxiety but a result 
of a neurological disorder, although the comorbidity with 
psychogenic factors is high and they may in fact play a sig-
nificant role in aggravation/maintenance of complaints. We 
also cannot neglect the hypothesis that the distress caused 
by these symptoms themselves may lead to depressive and 
anxious syndromes, and that may raise the “chicken and 
the egg” dilemma in some cases.
The etiology and pathophysiological mechanisms of BMS 
are still unclear, as well as effective forms of treatment, since 
total remission is unusual. Some pharmacological approaches 
were described, but there is a lack of clinical practice guide-
lines to follow to treat or alleviate BMS symptoms. Regard-
less of whether it is cause or consequence, the comorbidity 
with depression or anxiety is frequent and must be correctly 
addressed by the psychiatrist with drugs approved for their 
treatment. Since tricyclic, SSRI and SNRI antidepressants, as 
well as clonazepam, seem to be useful in BSM symptoms we 
suggest that the pharmacological approach should preferably 
begin with a choice between these drugs.
Responsabilidades Éticas
Conflitos de Interesse: Os autores declaram a inexistência de conflitos de interesse na realização do presente trabalho.
Fontes de Financiamento: Não existiram fontes externas de financiamento para a realização deste artigo.
Confidencialidade dos dados:  Os autores declaram ter seguido os protocolos da sua instituição acerca da publicação 
dos dados de doentes. 
Consentimento: Consentimento do doente para publicação obtido.
Proveniência e Revisão por Pares: Não comissionado; revisão externa por pares.
Ethical Disclosures 
Conflicts of Interest: The authors have no conflicts of interest to declare.
Financing Support: This work has not received any contribution, grant or scholarship.
Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication 
of data from patients.
Patient Consent: Consent for publication was obtained. 
Provenance and Peer Review: Not commissioned; externally peer reviewed.
References
1. de Souza FT, Teixeira AL, Amaral TM, dos Santos 
TP, Abreu MH, Silva TA, et al. Psychiatric disorders 
in burning mouth syndrome. J Psychosom Res. 2012; 
72:142 ‑6. doi: 10.1016/j.jpsychores.2011.11.008. 
2. Fedele S, Fricchione G, Porter SR, Mignogna MD. 
Burning mouth syndrome (stomatodynia). QJM. 2007; 
100:527 -30.
3. Abetz LM, Savage NW. Burning mouth syndrome 
and psychological disorders. Aust Dent J. 2009; 54: 
84 -93. doi: 10.1111/j.1834 ‑7819.2009.01099.x. 
4. Grushka M, Epstein JB, Gorsky M. Burning mouth 
syndrome. Am Fam Physician. 2002; 65:615 ‑620
5. Scala A, Checchi L, Montevecchi M, Marini I, Giam-
berardino MA. Update on burning mouth syndrome: 
overview and patient management. Crit Rev Oral Biol 
Med. 2003; 14:275 -91
6. Maltsman ‑Tseikhin A, Moricca P, Niv D. Burning 
mouth syndrome: will better understanding yield 
better management? Pain Pract. 2007; 7:151 ‑62. doi: 
10.1111/j.1533 ‑2500.2007.00124.x.
7. Cerchiari DP, Moricz RD, Sanjar FA, Rapoport PB, 
Moretti G, Guerra MM. Síndrome da boca ardente: 
etiologia. Rev Bras Otorrinolaringol. 2006; 72:419 ‑24.
